Vivus' Spedra for erectile dysfunction wins EU approval

06/28/2013 | PharmaTimes (U.K.)

The European Commission granted Vivus approval to market its PDE5 inhibitor Spedra, or avanafil, as a treatment for erectile dysfunction. The approval makes Spedra the first chemical entity cleared for treatment of ED in more than 10 years. The drug was approved in the U.S. more than a year ago, but has yet to be commercialized as Vivus looks for a partner.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI